229 related articles for article (PubMed ID: 36710583)
1. Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics.
Ma Z; Bolinger AA; Zhou J; Tian B
Expert Opin Ther Targets; 2023 Jan; 27(1):1-7. PubMed ID: 36710583
[TBL] [Abstract][Full Text] [Related]
2. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
To KKW; Xing E; Larue RC; Li PK
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
[TBL] [Abstract][Full Text] [Related]
3. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases.
Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J
Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293
[TBL] [Abstract][Full Text] [Related]
4. Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics.
Cai M; Dong J; Li H; Qin JJ
Curr Med Chem; 2022; 29(25):4391-4409. PubMed ID: 35152859
[TBL] [Abstract][Full Text] [Related]
5. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
6. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
Shanmugam V; Muthukrishnan S
J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases.
Wang Z; Yin L; Xiong Z; Huang F; Yang N; Jiang F; Li H; Cui Y; Ren J; Cheng Z; Jia K; Lu T; Zhu J; Hu Q; Chen Y
J Med Chem; 2023 Aug; 66(15):10824-10848. PubMed ID: 37478496
[TBL] [Abstract][Full Text] [Related]
8. Bromodomain inhibitors and therapeutic applications.
Gajjela BK; Zhou MM
Curr Opin Chem Biol; 2023 Aug; 75():102323. PubMed ID: 37207401
[TBL] [Abstract][Full Text] [Related]
9.
Nord JA; Wynia-Smith SL; Gehant AL; Jones Lipinski RA; Naatz A; Rioja I; Prinjha RK; Corbett JA; Smith BC
Front Endocrinol (Lausanne); 2022; 13():923925. PubMed ID: 36176467
[TBL] [Abstract][Full Text] [Related]
10. A patent review of BRD4 inhibitors (2013-2019).
Lu T; Lu W; Luo C
Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
[No Abstract] [Full Text] [Related]
11. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.
Liang D; Yu Y; Ma Z
Eur J Med Chem; 2020 Aug; 200():112426. PubMed ID: 32502863
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Novel Highly Specific Bromodomain-Containing Protein 4 Inhibitors in Innate Inflammation-Driven Airway Remodeling.
Tian B; Liu Z; Litvinov J; Maroto R; Jamaluddin M; Rytting E; Patrikeev I; Ochoa L; Vargas G; Motamedi M; Ameredes BT; Zhou J; Brasier AR
Am J Respir Cell Mol Biol; 2019 Jan; 60(1):68-83. PubMed ID: 30153047
[TBL] [Abstract][Full Text] [Related]
13. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
[TBL] [Abstract][Full Text] [Related]
14. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review).
Yongprayoon V; Wattanakul N; Khomate W; Apithanangsiri N; Kasitipradit T; Nantajit D; Tavassoli M
Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38606512
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases.
Kulikowski E; Rakai BD; Wong NCW
Med Res Rev; 2021 Jan; 41(1):223-245. PubMed ID: 32926459
[TBL] [Abstract][Full Text] [Related]
16. Emerging roles of bromodomain protein 4 in regulation of stem cell identity.
Dey A; Uppal S; Giri J; Misra HS
Stem Cells; 2021 Dec; 39(12):1615-1624. PubMed ID: 34520583
[TBL] [Abstract][Full Text] [Related]
17. Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.
Cooper JM; Patel AJ; Chen Z; Liao CP; Chen K; Mo J; Wang Y; Le LQ
Clin Cancer Res; 2019 Jun; 25(11):3404-3416. PubMed ID: 30796033
[TBL] [Abstract][Full Text] [Related]
18. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.
Zengerle M; Chan KH; Ciulli A
ACS Chem Biol; 2015 Aug; 10(8):1770-7. PubMed ID: 26035625
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.
Cribbs AP; Filippakopoulos P; Philpott M; Wells G; Penn H; Oerum H; Valge-Archer V; Feldmann M; Oppermann U
Front Immunol; 2021; 12():626255. PubMed ID: 33717143
[TBL] [Abstract][Full Text] [Related]
20. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives.
Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L
Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
